
    
      Single center, randomized, single dose, laboratory-blinded, 2-period, 2-sequence, crossover
      design to evaluate and compare the relative bioavailability and therefore the bioequivalence
      of three doses (400 mg, 600 mg and 800 mg) of eslicarbazepine acetate for two formulations
      (CTF versus TBM) after a single oral dose administration under fasting conditions
    
  